Evidence method
Level · gp.fundamentals.debt_to_revenue
825.79% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
VRCA · Jun 30, 2024
Verrica Pharmaceuticals Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-24-096669General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.21% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-315.97% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
2744.51% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
52.23% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
86.48% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-293.72% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
64.11% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
43.04% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History11 statesHistory building
Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/9 normalizedLevel 3Sep 30, 20240/5 normalizedLevel 3Dec 31, 20240/9 normalizedLevel 3Mar 31, 20250/8 normalizedLevel 3Jun 30, 20252/7 normalizedLevel 3Dec 31, 20257/8 normalizedLevel 3Mar 31, 20265/6 normalizedLevel 3Jun 30, 20265/6 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 1119.92%
- Current
- 825.79%
- Delta
- -294.13%
- Previous
- 0.00%
- Current
- 0.21%
- Delta
- 0.21%
- Previous
- -521.35%
- Current
- -315.97%
- Delta
- 205.38%
- Previous
- 65.32%
- Current
- 52.23%
- Delta
- -13.09%
- Previous
- 81.70%
- Current
- 86.48%
- Delta
- 4.77%
- Previous
- -486.12%
- Current
- -293.72%
- Delta
- 192.40%
- Previous
- 129.33%
- Current
- 64.11%
- Delta
- -65.22%
- Previous
- 54.16%
- Current
- 43.04%
- Delta
- -11.12%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · VRCA Fundamental State →Has State · Verrica Pharmaceuticals Inc. →Transitioned To · VRCA R_AND_D_INTENSITY_DECREASED →Transitioned To · VRCA SBC_INTENSITY_DECREASED →Transitioned To · VRCA Fundamental State →Transitioned To · VRCA BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · VRCA CAPEX_INTENSITY_INCREASED →Transitioned To · VRCA CASH_GENERATION_INCREASED →Transitioned To · VRCA INVENTORY_PRESSURE_DECREASED →Transitioned To · VRCA MARGIN_INCREASED →Transitioned To · VRCA PROFITABILITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.